What one share of Puma Biotechnology holds
We are a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. We are currently commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers.
Puma Biotechnology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.47 |
|---|---|
| Profit | $0.52 |
| Capex (buildings and equipment) | −$0.00 |
| Free cash flow | $0.79 |
| Cash and investments | $1.84 |
| Debt | $2.00 |
| Book value | $2.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | — | −$1.32 | $0.03 | −$0.27 | — | — |
| 2012 | — | −$3.42 | $0.02 | −$2.05 | — | $4.50 |
| 2013 | — | −$1.90 | $0.02 | −$1.94 | — | $2.90 |
| 2014 | — | −$4.73 | $0.04 | −$2.61 | — | $3.83 |
| 2015 | — | −$7.45 | $0.03 | −$4.84 | — | $6.35 |
| 2016 | — | −$8.29 | $0.13 | −$4.38 | — | $5.70 |
| 2017 | $0.74 | −$7.85 | $0.01 | −$4.65 | — | $1.42 |
| 2018 | $6.62 | −$2.99 | $0.01 | −$0.65 | — | $0.90 |
| 2019 | $7.02 | −$1.95 | $0.01 | $0.57 | — | $0.45 |
| 2020 | $5.69 | −$1.52 | $0.00 | $0.02 | — | −$0.15 |
| 2021 | $6.23 | −$0.72 | $0.00 | $0.51 | — | −$0.06 |
| 2022 | $5.08 | $0.00 | $0.00 | −$0.35 | — | $0.47 |
| 2023 | $4.96 | $0.45 | $0.00 | $0.57 | — | $1.12 |
| 2024 | $4.69 | $0.62 | $0.00 | $0.79 | — | $1.88 |
| 2025 | $4.51 | $0.61 | $0.00 | $0.82 | — | $2.59 |
Common questions about Puma Biotechnology
How much does one share of Puma Biotechnology earn?
Over the last 12 months, each share of Puma Biotechnology earned $0.52 of profit on $4.47 of sales, keeping about 12¢ of every $1 (profit margin).
Does Puma Biotechnology pay a dividend?
Puma Biotechnology didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Puma Biotechnology’s book value per share?
Puma Biotechnology’s book value is $2.71 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Puma Biotechnology have?
Each share of Puma Biotechnology has $1.84 of cash and investments and $2.00 of debt, as of June 30, 2026.
What is Puma Biotechnology’s free cash flow per share?
$0.79 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Puma Biotechnology bought back shares?
Puma Biotechnology’s share count rose about 554% from 2011 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.